Scarica l'app Stockscreener
21.11
1.20%
0.25
Dopo l'orario di chiusura:
21.10
-0.010
-0.05%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARQT Giù?
Forum
Previsione
Arcutis Biotherapeutics Inc Borsa (ARQT) Ultime notizie
Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference - Yahoo Finance
ARQT News | ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) - ChartMill
Arcutis Biotherapeutics (ARQT) Price Target Increased by 32.62% to 31.62 - MSN
How (ARQT) Movements Inform Risk Allocation Models - Stock Traders Daily
Number of shareholders of Arcutis Biotherapeutics, Inc. – NASDAQ:ARQT - TradingView
Arcutis Biotherapeutics: The Dermatology Platform Is Starting To Compound (NASDAQ:ARQT) - Seeking Alpha
Arcutis Biotherapeutics, Inc.Common stock (NQ: ARQT - FinancialContent
Arcutis Biotherapeutics SVP CFO Latha Vairavan sells $9,156 in stock. - Investing.com UK
Arcutis EVP, CMO Burnett sells $4,673 in common stock - Investing.com UK
Arcutis Biotherapeutics SVP CFO Latha Vairavan sells $9,156 in stock. By Investing.com - Investing.com Nigeria
Arcutis EVP, CMO Burnett sells $4,673 in common stock By Investing.com - Investing.com South Africa
Arcutis (ARQT) CFO tax-related sale of 435 shares after RSU vesting - Stock Titan
Arcutis Biotherapeutics (ARQT) officer sells 222 shares to cover RSU tax - Stock Titan
Arcutis Q1 2026 slides: revenue surges 65% amid expansion push By Investing.com - Investing.com Nigeria
Arcutis Q1 2026 slides: revenue surges 65% amid expansion push - Investing.com
Earnings call transcript: Arcutis Biotherapeutics Q1 2026 misses EPS expectations By Investing.com - Investing.com South Africa
Earnings call transcript: Arcutis Biotherapeutics Q1 2026 misses EPS expectations - Investing.com Nigeria
State Street (NYSE: STT) holds 6.30M shares of Arcutis (5.1%) - Stock Titan
Arcutis Biotherapeutics (ARQT) Form 144: Patrick Burnett reports share dispositions - Stock Titan
Arcutis Biotherapeutics (ARQT) Form 144 lists 435 vested shares for resale - Stock Titan
H.C. Wainwright Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $34 - Moomoo
Arcutis Earnings Call Signals Momentum Amid Headwinds - TipRanks
FDA Approval for ZORYVE issued to ARCUTIS BIOTHERAPEUTICS INC - Quantisnow
Arcutis outlines $480M-$495M 2026 revenue guidance while expanding ZORYVE sales teams - MSN
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Arcutis Biotherapeutics (ARQT) Is Down 11.0% After Strong Q1 And sNDA For ZORYVE Expansion - Yahoo Finance
40 new Arcutis hires receive stock units and options under Nasdaq rule - Stock Titan
Prudential Financial (ARQT) reports 5.30M-share stake; Jennison holds 4.98M - Stock Titan
ARQT SEC FilingsArcutis Biotherapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Arcutis Biotherapeutics (ARQT) Reports Strong Q1 2026 Earnings w - GuruFocus
ARQT Reiterates by Needham -- Price Target Maintained at $36.00 - GuruFocus
TD Cowen Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35 - Moomoo
A Quick Look at Today's Ratings for Arcutis Biotherapeutics(ARQT.US), With a Forecast Between $34 to $36 - Moomoo
Arcutis Biotherapeutics, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Needham Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $36 - Moomoo
Arcutis Biotherapeutics Reaffirmed at Buy as Growth Outlook Strengthens; $36 Price Target Maintained - TipRanks
Arcutis Biotherapeutics CMO sells $16,149 in shares By Investing.com - Investing.com Australia
Arcutis Biotherapeutics, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:ARQT) 2026-05-07 - Seeking Alpha
Arcutis Biotherapeutics EVP Masaru Matsuda sells $192k in stock By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics SVP CFO Latha Vairavan sells $31,661 in stock By Investing.com - Investing.com Australia
Arcutis Biotherapeutics EVP Masaru Matsuda sells $192k in stock - Investing.com UK
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):